Here is an estimate for annual sales of over $2 billion, wow! http://finfeed.com/biotech/mvp-back-radar-striking-korea-distribution-agreement/20160907/
They include countries that have not yet given approval for Penthrox sales. They don't estimate how long this will take, maybe 10, 15 20 years. It will be one heck of a ride if they are correct.
They say the next surge in share price will be approval for sales in France which are expected next month.
It is a bit of fun to play with the numbers. NPAT as % revenue for last two years was 10% for 2016 and 13% for 2015. The profit margin will probably increase when they get the new factory operating and as sales increase, lets say to 15%. On sales of $2B thats $300m. Give them a PE of 15 and we get a very large number for market cap and share price. Maybe I or they are dreaming, but I am going for the DRP.
MVP Price at posting:
$5.09 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)